SELP has also been proposed as a target therapy for metabolic syndrome, while increased levels of integrin beta 2 in adipose tissue and blood have been observed in diet-induced obesity (Patel et al., 2017; Mesgari-Abbasi et al., 2021; Wu et al., 2010). Here, ITGB2 is linked to obesity disorder.